

INDUSTRY-SPONSORED SYMPOSIUM | IASLC ASIA

FRIDAY 28TH OCTOBER AT 12:00 – 13:00

ROOM 203, NARA PREFECTURAL CONVENTION CENTER, JAPAN & ONLINE

DECISIVE MOMENTS IN THE TREATMENT OF MET EXON 14 SKIPPING NSCLC

Faculty



Prof. Terufumi Kato (Chair)

Kanagawa Cancer Center,
Yokohama, Japan



Prof. Yasushi Goto

National Cancer Center Hospital,
Tokyo, Japan



Prof. Nir Peled

The Institute of Oncology,
Shaare Zedek Medical Center,
Jerusalem, Israel



Prof. James Yang

National Taiwan University
Cancer Center, Taipei, Taiwan

Agenda

A moment to welcome you

Take a moment to consider identification and treatment

Plenary session

A moment of clarity: Has our VISION¹ for MET exon 14 skipping become a reality?

Plenary session

A moment to examine treatment outcomes and the VISION¹ study in Asian patients

Plenary session

Make every moment matter: Optimizing treatment

Panel discussion

A moment to reflect on MET exon 14 skipping

Audience

Multidisciplinary team members with an interest in the management of patients with MET exon 14 skipping NSCLC

Meeting Objectives

- To highlight the importance of testing for MET exon 14 skipping in patients with NSCLC
- To examine recent evidence describing the efficacy and safety of tepotinib from the VISION¹ study
- To share practical insight into the management of these patients during panel discussions

This Industry-Sponsored Symposium is organized and sponsored by Merck Healthcare KGaA.

This program was approved by the IASLC 2022 Asia Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 Asia Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC-accredited program.

Healthcare professionals, please check your locally approved Product Information.

© Merck Healthcare KGaA, Darmstadt, Germany. All rights reserved. September 2022. GL-TEP-00251.

Reference: 1. Paik PK et al. *N Engl J Med* 2020; 383:931–943.

